Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Repatha Performance Contracting: Sweetening The Pot For Payers

Executive Summary

Amgen suggests it would respond to payer price concerns by pursuing contracts that tie the drug’s net cost (after rebates) to its value in the relatively narrow population it is indicated for. Some payers eye choosing either Repatha or rival Praluent based on price.

Advertisement

Related Content

Praluent Coverage: Being First May Not Matter As Payers Await Repatha

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel